Cardiovascular risk evaluation and antiretroviral therapy effects in an HIV cohort: Implications for clinical management: The CREATE 1 study

International Journal of Clinical Practice

Volumn 64, Issue 9, 2010, Pages 1252-1259

  Aboud, M ^a   Elgalib, A ^a   Pomeroy, L ^a   Panayiotakopoulos, G ^a   Skopelitis, E ^a   Kulasegaram, R ^a   Dimian, C ^b   Lampe, F C ^c   Duncan, A ^a   Wierzbicki, A S ^a   Peters, B S ^d  

^a GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^b Beckenham Hospital   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN;

ADULT; ARTICLE; CARDIOVASCULAR RISK; ETHNIC DIFFERENCE; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK ASSESSMENT; SEX DIFFERENCE; SYSTOLIC BLOOD PRESSURE; UNITED KINGDOM;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CARDIOVASCULAR DISEASES; CHOLESTEROL; COHORT STUDIES; CORONARY DISEASE; CROSS-SECTIONAL STUDIES; FEMALE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; RISK ASSESSMENT; RISK FACTORS; SMOKING;

EID: 77954655864     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2010.02424.x     Document Type: Article

References (38)

1. Bozzette SA, Ake CF, Tam HK et al. Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection. N Engl J Med 2003 348 : 702 710.
2. Braitstein P, Yip B, Heath KV et al. Interventional cardiovascular procedures among HIV-infected individuals on antiretroviral therapy 1995-2000. AIDS 2003 17 : 2071 2075.
3. Dube MP, Sprecher D, Henry WK et al. Preliminary guidelines for the evaluation and management of dyslipidemia in adults infected with human immunodeficiency virus and receiving antiretroviral therapy: recommendations of the Adult AIDS Clinical Trial Group Cardiovascular Disease Focus Group. Clin Infect Dis 2000 31 : 1216 1224.
4. Currier JS. Cardiovascular risk associated with HIV therapy. J Acquir Immune Defic Syndr 2002 31 (Suppl. 1 S16 23.
5. Kulasegaram R, Peters BS, Wierzbicki AS. Dyslipidaemia and cardiovascular risk in HIV infection. Curr Med Res Opin 2005 21 : 1717 1725.
6. Aboud M, Elgalib A, Kulasegaram R et al. Insulin resistance and HIV infection: a review. Int J Clin Pract 2007 61 : 463 472.
7. Wierzbicki AS, Purdon SD, Hardman TC et al. HIV lipodystrophy and its metabolic consequences: implications for clinical practice. Curr Med Res Opin 2008 24 : 609 624.
8. Currier JS, Lundgren JD, Carr A et al. Epidemiological evidence for cardiovascular disease in HIV-infected patients and relationship to highly active antiretroviral therapy. Circulation 2008 118 : e29 35.
9. Vascular Programme. Putting Prevention First - Vascular Checks: Risk Assessment and Management.
10. Anderson KM, Odell PM, Wilson PW et al. Cardiovascular disease risk profiles. Am Heart J 1991 121 (1 Pt 2 293 298.
11. Hippisley-Cox J, Coupland C, Vinogradova Y et al. Predicting cardiovascular risk in England and Wales: prospective derivation and validation of QRISK2. BMJ 2008 336 : 1475 1482.
12. Conroy RM, Pyorala K, Fitzgerald AP et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 2003 24 : 987 1003.
13. Wierzbicki AS, Reynolds TM. Vascular risk screening: possible or too much, too soon? Int J Clin Pract 2009 63 : 989 996.
14. Bergersen BM, Sandvik L, Bruun JN et al. Elevated Framingham risk score in HIV-positive patients on highly active antiretroviral therapy: results from a Norwegian study of 721 subjects. Eur J Clin Microbiol Infect Dis 2004 23 : 625 630.
15. Friis-Moller N, Weber R, Reiss P et al. Cardiovascular disease risk factors in HIV patients - association with antiretroviral therapy. Results from the DAD study. AIDS 2003 17 : 1179 1193.
16. Law MG, Friis-Moller N, El-Sadr WM et al. The use of the Framingham equation to predict myocardial infarctions in HIV-infected patients: comparison with observed events in the D:A:D Study. HIV Med 2006 7 : 218 230.
17. British Cardiac Society, British Hypertension Society, Diabetes UK et al. JBS 2: the Joint British Societies' guidelines for prevention of cardiovascular disease in clinical practice. Heart 2005 91 (Suppl. 5 v1 52.
18. National Institute for Health and Clinical Excellence. Lipid Modification.
19. EMIS National User Group. University of Nottingham. QResearch Database. QResearch Group 2009. http://www.qresearch.org (accessed July 2009).
20. Neil HA, Perera R, Armitage JM et al. Estimated 10-year cardiovascular risk in a British population: results of a national screening project. Int J Clin Pract 2008 62 : 1322 1331.
21. Friis-Moller N, Sabin CA, Weber R et al. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med 2003 349 : 1993 2003.
22. De Socio GV, Martinelli L, Morosi S et al. Is estimated cardiovascular risk higher in HIV-infected patients than in the general population? Scand J Infect Dis 2007 39 : 805 812.
23. De Socio GV, Parruti G, Quirino T et al. Identifying HIV patients with an unfavorable cardiovascular risk profile in the clinical practice: results from the SIMONE study. J Infect 2008 57 : 33 40.
24. Knobel H, Jerico C, Montero M et al. Global cardiovascular risk in patients with HIV infection: concordance and differences in estimates according to three risk equations (Framingham, SCORE, and PROCAM). AIDS Patient Care STDS 2007 21 : 452 457.
25. Law M, Friis-Moller N, Weber R et al. Modelling the 3-year risk of myocardial infarction among participants in the Data Collection on Adverse Events of Anti-HIV Drugs (DAD) study. HIV Med 2003 4 : 1 10.
26. Brindle P, May M, Gill P et al. Primary prevention of cardiovascular disease: a web-based risk score for seven British black and minority ethnic groups. Heart 2006 92 : 1595 1602.
27. Steyn K, Levitt NS, Hoffman M et al. The global cardiovascular diseases risk pattern in a peri-urban working-class community in South Africa. The Mamre study. Ethn Dis 2004 14 : 233 242.
28. Cappuccio FP, Oakeshott P, Strazzullo P et al. Application of Framingham risk estimates to ethnic minorities in United Kingdom and implications for primary prevention of heart disease in general practice: cross sectional population based study. BMJ 2002 325 : 1271.
29. Triant VA, Lee H, Hadigan C et al. Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease. J Clin Endocrinol Metab 2007 92 : 2506 2512.
30. Reynolds TM, Twomey P, Wierzbicki AS. Accuracy of cardiovascular risk estimation in patients without diabetes. J Cardiovasc Risk 2002 9 : 183 190.
31. Hsue PY, Lo JC, Franklin A et al. Progression of atherosclerosis as assessed by carotid intima-media thickness in patients with HIV infection. Circulation 2004 109 : 1603 1608.
32. de Saint ML, Vandhuick O, Guillo P et al. Premature atherosclerosis in HIV positive patients and cumulated time of exposure to antiretroviral therapy (SHIVA study). Atherosclerosis 2006 185 : 361 367.
33. Currier JS, Lundgren JD. Guidelines for managing cardiovascular risk: an evolving area. Curr Opin HIV AIDS 2008 3 : 205 206.
34. Carr A, Hudson J, Chuah J et al. HIV protease inhibitor substitution in patients with lipodystrophy: a randomized, controlled, open-label, multicentre study. AIDS 2001 15 : 1811 1822.
35. Barragan P, Fisac C, Podzamczer D. Switching strategies to improve lipid profile and morphologic changes. AIDS Rev 2006 8 : 191 203.
36. Colafigli M, Di GS, Bracciale L et al. Cardiovascular risk score change in HIV-1-infected patients switched to an atazanavir-based combination antiretroviral regimen. HIV Med 2008 9 : 172 179.
37. Bentue-Ferrer D, Arvieux C, Tribut O et al. Clinical pharmacology, efficacy and safety of atazanavir: a review. Expert Opin Drug Metab Toxicol 2009 5 : 1455 1468.
38. Markowitz M, Nguyen BY, Gotuzzo E et al. Rapid and durable antiretroviral effect of the HIV-1 integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study. J Acquir Immune Defic Syndr 2007 46 : 125 133.